Perspective Therapeutics, Inc. (CATX)

NYSEAMERICAN: CATX · Real-Time Price · USD
3.710
-0.290 (-7.25%)
Dec 4, 2024, 4:00 PM EST - Market closed
-7.25%
Market Cap 250.75M
Revenue (ttm) 1.56M
Net Income (ttm) -63.79M
Shares Out 67.59M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,646,355
Open 4.010
Previous Close 4.000
Day's Range 3.670 - 4.030
52-Week Range 2.300 - 19.100
Beta 1.14
Analysts Strong Buy
Price Target 17.25 (+364.96%)
Earnings Date Nov 12, 2024

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-α-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as L... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1983
Employees 119
Stock Exchange NYSEAMERICAN
Ticker Symbol CATX
Full Company Profile

Financial Performance

In 2023, Perspective Therapeutics's revenue was $1.43 million, a decrease of -73.52% compared to the previous year's $5.42 million. Losses were -$46.51 million, 332.2% more than in 2022.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price forecast is $17.25, which is an increase of 364.96% from the latest price.

Price Target
$17.25
(364.96% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

7 days ago - GlobeNewsWire

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

13 days ago - GlobeNewsWire

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

19 days ago - GlobeNewsWire

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering...

22 days ago - GlobeNewsWire

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

5 weeks ago - GlobeNewsWire

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

6 weeks ago - GlobeNewsWire

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

7 weeks ago - GlobeNewsWire

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics, Inc. CATX is down 13% at $11.53 at last check Friday.

7 weeks ago - Benzinga

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

7 weeks ago - GlobeNewsWire

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

7 weeks ago - GlobeNewsWire

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

2 months ago - GlobeNewsWire

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of ...

2 months ago - Seeking Alpha

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close o...

2 months ago - GuruFocus

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

2 months ago - GlobeNewsWire

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

3 months ago - GlobeNewsWire

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

3 months ago - GlobeNewsWire

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

4 months ago - GlobeNewsWire

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

4 months ago - GlobeNewsWire

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout...

4 months ago - GlobeNewsWire

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

6 months ago - GlobeNewsWire

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

6 months ago - GlobeNewsWire

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

6 months ago - GlobeNewsWire

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...

6 months ago - GlobeNewsWire

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...

7 months ago - GlobeNewsWire

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...

7 months ago - GlobeNewsWire